Improved CAR-T cell targeting of cancer

Bidragets beskrivning

Chimeric antigen receptor (CAR)-T cell therapy is a promising new approach for treating cancer, where an engineered CAR molecule is introduced into patient's immune cells to direct them to destroy cancer cells. CAR-T cell therapy has been very successful in treating leukemias and lymphomas. However, most cancers lack any truly cancer-specific determinants, and it has been difficult to create CAR-T cells that would efficiently kill cancer without attacking healthy tissues. Our laboratory has developed a new and highly tunable targeting technology based on a small protein module, known as the SH3 domain. We have already shown that using modified SH3 domains it is possible to create CAR-T cells that can sense even relative differences between cancer and normal cell surface structures. Here we propose a series of experiments designed to exploit this opportunity in order to develop potent but safe CAR-T cell therapies for ovarian and other cancers that have remained difficult to treat.
Visa mer

Startår

2020

Slutår

2024

Beviljade finansiering

Kalle Saksela Orcid -palvelun logo
518 340 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt

Övriga uppgifter

Finansieringsbeslutets nummer

331787

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Identifierade teman

cancer